PMID- 23818456
OWN - NLM
STAT- MEDLINE
DCOM- 20140429
LR  - 20150330
IS  - 1752-8984 (Electronic)
IS  - 1479-1641 (Linking)
VI  - 10
IP  - 5
DP  - 2013 Sep
TI  - Adiponectin in coronary heart disease and newly diagnosed impaired glucose 
      tolerance.
PG  - 452-8
LID - 10.1177/1479164113490179 [doi]
AB  - OBJECTIVE: Adiponectin is produced by adipose tissue and regarded as protective 
      hormone for diabetes and coronary heart disease (CHD). Its role in heart failure 
      is discussed controversially. METHODS: In this study, 1015 consecutive patients 
      admitted for acute (n = 149) or elective (n = 866) coronary angiography were 
      enrolled. Patients with known diabetes mellitus (DM) were excluded. All patients 
      were classified by oral glucose tolerance test (oGTT) according to World Health 
      Organization (WHO) criteria and by the results of coronary angiography as 
      no/minor coronary heart disease (CHD), single-vessel disease (1-VD), 
      double-vessel disease (2-VD) or triple-vessel disease (3-VD), by New York Heart 
      Association (NYHA) criteria and by echocardiography for heart failure. 
      Adiponectin and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels were 
      measured in all patients. RESULTS: Adiponectin was higher in patients with normal 
      glucose tolerance (NGT) (13.65 +/- 10.31 mg/l) compared to impaired glucose 
      tolerance (IGT) (11.12 +/- 7.5, p < 0.001) or diabetes (11.22 +/- 7.63, p < 0.001). 
      There was a stepwise decrease in adiponectin from no CHD (18.16 +/- 12.49 mg/L) to 
      minor CHD (16.01 +/- 11.42) to 1-VD (12.18 +/- 8.8, p < 0.001 to no/minor CHD) to 2- 
      and 3-VD (10.68 +/- 7.5, p < 0.001 to no/minor CHD, p = 0.004 to 1-VD). Patients 
      with heart failure NYHA III (17.4 +/- 10.27) had higher adiponectin levels compared 
      to NYHA II (12.94 +/- 9.41, p < 0.001 to NYHA III) and NYHA I (10.3 +/- 7.75, p < 
      0.001 to NYHA III/II). In this line, adiponectin levels were positively 
      correlated to NT-proBNP levels (r = 0.303), and patients with ejection fraction 
      (EF) < 50% had higher adiponectin levels than those with EF > 50% (14.96 +/- 4.35 
      to 11.78 +/- 3.71, p = 0.006). CONCLUSION: Adiponectin levels are inversely 
      correlated to progressing CHD and glucose intolerance but positively correlated 
      to increasing heart failure.
FAU - Azizi Ghanbari, Aline
AU  - Azizi Ghanbari A
AD  - Department of Medicine, Municipal Hospital of Dresden-Neustadt, Dresden, Germany.
FAU - Dorr, Rolf
AU  - Dorr R
FAU - Spitzer, Stefan
AU  - Spitzer S
FAU - Stumpf, Juergen
AU  - Stumpf J
FAU - Britz, Andreas
AU  - Britz A
FAU - Amann-Zalan, Ildiko
AU  - Amann-Zalan I
FAU - Lodwig, Volker
AU  - Lodwig V
FAU - Ulm, Bernhard
AU  - Ulm B
FAU - Schnell, Oliver
AU  - Schnell O
FAU - Lohmann, Tobias
AU  - Lohmann T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130701
PL  - England
TA  - Diab Vasc Dis Res
JT  - Diabetes & vascular disease research
JID - 101234011
RN  - 0 (Adiponectin)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Adiponectin/*metabolism
MH  - Aged
MH  - Aged, 80 and over
MH  - Coronary Disease/complications/*metabolism
MH  - Diabetes Mellitus/metabolism
MH  - Female
MH  - Glucose/metabolism
MH  - Glucose Intolerance/diagnosis/*metabolism
MH  - Heart Failure/complications
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/metabolism
OTO - NOTNLM
OT  - Adiponectin
OT  - coronary heart disease
OT  - diabetes mellitus
OT  - heart failure
EDAT- 2013/07/03 06:00
MHDA- 2014/04/30 06:00
CRDT- 2013/07/03 06:00
PHST- 2013/07/03 06:00 [entrez]
PHST- 2013/07/03 06:00 [pubmed]
PHST- 2014/04/30 06:00 [medline]
AID - 1479164113490179 [pii]
AID - 10.1177/1479164113490179 [doi]
PST - ppublish
SO  - Diab Vasc Dis Res. 2013 Sep;10(5):452-8. doi: 10.1177/1479164113490179. Epub 2013 
      Jul 1.